90651

Human Papillomavirus vaccine, types 6, 11, 16, 18, 31, 33, 45, 52, 58, nonavalent (9vHPV), 2 or 3 dose schedule, for intramuscular use

CPT 90651 refers to the nonavalent human papillomavirus (9vHPV) vaccine, commercially known as Gardasil 9. This vaccine is a complex biological product designed to provide robust immune protection against nine specific types of HPV that are responsible for the vast majority of HPV-related malignancies and benign lesions. Specifically, types 16, 18, 31, 33, 45, 52, and 58 are identified as high-risk strains, which are the primary causative agents in cervical, vulvar, vaginal, anal, and oropharyngeal cancers. Types 6 and 11 are categorized as low-risk strains but are responsible for approximately 90% of all cases of genital warts (condyloma acuminata). The vaccine is formulated using purified virus-like particles (VLPs) composed of the L1 protein of each HPV type. Because these VLPs contain no viral genetic material, the vaccine is non-infectious and cannot cause HPV-related diseases. The procedural application involves a 0.5 mL intramuscular injection, usually delivered into the deltoid muscle of the upper arm. The administration protocol varies by age; individuals initiating the series between ages 9 and 14 typically follow a two-dose schedule (0 and 6-12 months), whereas individuals aged 15 through 45, or those with immunocompromising conditions, require a three-dose series (0, 2, and 6 months). Clinical data indicates that the nonavalent vaccine offers a broader spectrum of protection than its quadrivalent predecessor (90649), potentially preventing up to 90% of cervical cancers worldwide. Providers are required to maintain meticulous documentation of the vaccine manufacturer, lot number, expiration date, and the specific injection site to ensure patient safety and regulatory compliance.

Clinical Indications

  • Prevention of cervical, vulvar, and vaginal cancers in females
  • Prevention of anal cancer in both males and females
  • Prevention of oropharyngeal and other head and neck cancers
  • Prevention of genital warts (condyloma acuminata)
  • Prevention of cervical intraepithelial neoplasia (CIN) grades 1, 2, and 3
  • Prevention of vulvar intraepithelial neoplasia (VIN) and vaginal intraepithelial neoplasia (VaIN)
  • Routine immunization for adolescents starting at age 11 or 12 years
  • Catch-up vaccination for adults through age 45 years

Procedure Steps

  1. Confirm patient identity and verify immunization history in the medical record or state registry.
  2. Screen for contraindications including hypersensitivity to yeast or any vaccine component.
  3. Distribute the current Human Papillomavirus Vaccine Information Statement (VIS) to the patient or legal guardian.
  4. Assess the patient for acute illness; minor illnesses without fever are not typically contraindications.
  5. Thoroughly shake the prefilled syringe or single-dose vial to ensure a uniform, cloudy white suspension.
  6. Aseptically prepare the injection site, usually the deltoid, using an alcohol swab.
  7. Perform a 0.5 mL intramuscular injection at a 90-degree angle using an appropriate needle length for the patient's body mass.
  8. Apply pressure to the injection site after needle withdrawal; do not massage.
  9. Dispose of the needle and syringe in a biohazardous sharps container immediately.
  10. Monitor the patient for at least 15 minutes post-administration for signs of syncope or hypersensitivity reactions.
  11. Record the date, dose number, site, manufacturer, lot number, and administrator credentials in the EHR.

Coding Guidelines

  • CPT 90651 represents the vaccine product only; it must be reported in conjunction with an administration code.
  • For pediatric patients (under 19) receiving counseling, use administration codes 90460 (first component) and 90461 (subsequent components).
  • For adult patients or when counseling is not documented, use administration codes 90471 (initial IM injection) and 90472 (each additional IM injection).
  • If the vaccine is the only reason for the visit, do not report an Evaluation and Management (E/M) code.
  • If a significant, separately identifiable E/M service is performed, append modifier 25 to the E/M code (e.g., 99213-25).
  • The 90651 code should not be reported if the quadrivalent (90649) or bivalent (90650) vaccine is administered.
  • Ensure the diagnosis code Z23 is linked to both the vaccine product and the administration code.

Associated ICD-10 Codes